elfosscientiae.cigb.edu.cuelfosscientiae.cigb.edu.cu/PDFs/Biotecnol Apl/1997/14/3/185-188.pdf ·...
4
Transcript of elfosscientiae.cigb.edu.cuelfosscientiae.cigb.edu.cu/PDFs/Biotecnol Apl/1997/14/3/185-188.pdf ·...
![Page 1: elfosscientiae.cigb.edu.cuelfosscientiae.cigb.edu.cu/PDFs/Biotecnol Apl/1997/14/3/185-188.pdf · viduals and predicting progression to ADS (4-9). Among the persons with 1--ÐV infection](https://reader030.fdocuments.us/reader030/viewer/2022040908/5e802d58f6df6521be07a344/html5/thumbnails/1.jpg)
![Page 2: elfosscientiae.cigb.edu.cuelfosscientiae.cigb.edu.cu/PDFs/Biotecnol Apl/1997/14/3/185-188.pdf · viduals and predicting progression to ADS (4-9). Among the persons with 1--ÐV infection](https://reader030.fdocuments.us/reader030/viewer/2022040908/5e802d58f6df6521be07a344/html5/thumbnails/2.jpg)
![Page 3: elfosscientiae.cigb.edu.cuelfosscientiae.cigb.edu.cu/PDFs/Biotecnol Apl/1997/14/3/185-188.pdf · viduals and predicting progression to ADS (4-9). Among the persons with 1--ÐV infection](https://reader030.fdocuments.us/reader030/viewer/2022040908/5e802d58f6df6521be07a344/html5/thumbnails/3.jpg)
![Page 4: elfosscientiae.cigb.edu.cuelfosscientiae.cigb.edu.cu/PDFs/Biotecnol Apl/1997/14/3/185-188.pdf · viduals and predicting progression to ADS (4-9). Among the persons with 1--ÐV infection](https://reader030.fdocuments.us/reader030/viewer/2022040908/5e802d58f6df6521be07a344/html5/thumbnails/4.jpg)